리니지 셀 테라퓨틱스, Inc.
US ˙ NYSEAM ˙ US53566P1093

SecurityLCTX / Lineage Cell Therapeutics, Inc.
InstitutionCommonwealth Equity Services, Inc
Latest Disclosed Ownership60,091 shares
Latest Disclosed Value $ 171,000
Commonwealth Equity Services, Inc ownership in LCTX / Lineage Cell Therapeutics, Inc.

On February 16, 2018 - Commonwealth Equity Services, Inc filed a 13F-HR/A form disclosing ownership of 60,091 shares of Lineage Cell Therapeutics, Inc. (US:LCTX) valued at $158,532 USD as of September 30, 2017. The entity filed a previous 13F-HR/A on February 16, 2018 disclosing 60,091 shares of Lineage Cell Therapeutics, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $71,508 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2018-02-16 2017-09-30 13F/A-1 BIOTIME COM 09066L105 60,091 0 0.00 171 -9.52 0.0010
2017-11-07 2017-09-30 13F BIOTIME COM 09066L105 60,091 0 170
2018-02-16 2017-06-30 13F/A-1 BIOTIME COM 09066L105 60,091 37,442 165.31 189 142.31 0.0012
2017-08-11 2017-06-30 13F BIOTIME COM 09066L105 60,091 37,442 189
2018-02-16 2017-03-31 13F/A-1 BIOTIME COM 09066L105 22,649 2,600 12.97 78 8.33 0.0005
2017-05-15 2017-03-31 13F BIOTIME COM 09066L105 22,649 2,600 78
2018-02-16 2016-12-31 13F/A-1 BIOTIME COM 09066L105 20,049 20,049 74.34 72 63.64 0.0005
2017-02-01 2016-12-31 13F BIOTIME COM 09066L105 20,049 72
2014-02-11 2013-12-31 13F BIOTIME COM 09066L105 0 -11,500 -100.00 0 -100.00
2013-11-04 2013-09-30 13F BIOTIME COM 09066L105 11,500 -2,250 -16.36 44 -18.52 0.0007
2013-07-29 2013-06-30 13F BIOTIME COM 09066L105 13,750 54
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.